Novartis (NVS) to Release Quarterly Earnings on Tuesday

Key Points

• Novartis is set to announce its Q3 2025 earnings on October 28th, with analysts predicting earnings of $2.28 per share and revenue of $13.7011 billion.
• The stock price opened at $131.78, with a 12-month high of $133.55 and a market capitalization of $278.38 billion.
• Wall Street analysts have mixed ratings for Novartis, with one Strong Buy, two Buy, four Hold, and three Sell ratings, leading to an average target price of $120.33.

Novartis (NYSE:NVS - Get Free Report) is expected to be announcing its Q3 2025 results before the market opens on Tuesday, October 28th. Analysts expect the company to announce earnings of $2.28 per share and revenue of $13.7011 billion for the quarter. Investors are encouraged to explore the company's upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Tuesday, October 28, 2025 at 9:00 AM ET.

Novartis Price Performance

Novartis stock opened at $131.78 on Tuesday. Novartis has a 12-month low of $96.06 and a 12-month high of $133.55. The stock has a market capitalization of $278.38 billion, a P/E ratio of 19.18, a P/E/G ratio of 1.82 and a beta of 0.64. The firm's 50-day moving average is $126.80 and its two-hundred day moving average is $118.80. The company has a debt-to-equity ratio of 0.53, a current ratio of 0.82 and a quick ratio of 0.62.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on NVS shares. The Goldman Sachs Group reaffirmed a "sell" rating and set a $118.00 price target (down from $119.00) on shares of Novartis in a research note on Friday, September 12th. Deutsche Bank Aktiengesellschaft reissued a "buy" rating on shares of Novartis in a research report on Thursday, August 21st. Weiss Ratings reissued a "buy (b)" rating on shares of Novartis in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Novartis from a "buy" rating to a "strong-buy" rating in a research report on Saturday, October 11th. Finally, Morgan Stanley raised shares of Novartis from an "underweight" rating to an "equal weight" rating and set a $123.00 target price on the stock in a research report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, four have assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $120.33.

Institutional Trading of Novartis

Hedge funds have recently made changes to their positions in the company. Tower Research Capital LLC TRC grew its position in shares of Novartis by 1,776.5% during the second quarter. Tower Research Capital LLC TRC now owns 1,595 shares of the company's stock worth $193,000 after buying an additional 1,510 shares in the last quarter. Binnacle Investments Inc increased its stake in shares of Novartis by 8.5% in the second quarter. Binnacle Investments Inc now owns 1,769 shares of the company's stock worth $214,000 after buying an additional 138 shares during the last quarter. Transamerica Financial Advisors LLC increased its stake in shares of Novartis by 51.5% in the second quarter. Transamerica Financial Advisors LLC now owns 2,077 shares of the company's stock worth $251,000 after buying an additional 706 shares during the last quarter. Two Sigma Securities LLC bought a new stake in shares of Novartis in the second quarter worth $340,000. Finally, Lantern Wealth Advisors LLC bought a new stake in shares of Novartis in the second quarter worth $351,000. Hedge funds and other institutional investors own 13.12% of the company's stock.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.